|
1
|
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
|
Lancet
|
2002
|
16.56
|
|
2
|
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
|
N Engl J Med
|
2015
|
15.06
|
|
3
|
Class of antiretroviral drugs and the risk of myocardial infarction.
|
N Engl J Med
|
2007
|
12.93
|
|
4
|
Combination antiretroviral therapy and the risk of myocardial infarction.
|
N Engl J Med
|
2003
|
12.23
|
|
5
|
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
|
Arch Intern Med
|
2006
|
9.21
|
|
6
|
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
|
Lancet
|
2008
|
8.73
|
|
7
|
Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.
|
Lancet
|
2008
|
7.70
|
|
8
|
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
|
AIDS
|
2003
|
5.61
|
|
9
|
Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.
|
Crit Care Med
|
2011
|
5.28
|
|
10
|
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
|
AIDS
|
2005
|
4.40
|
|
11
|
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
|
Lancet
|
2004
|
3.59
|
|
12
|
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
|
Lancet Infect Dis
|
2011
|
3.59
|
|
13
|
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.
|
AIDS
|
2010
|
3.47
|
|
14
|
The role of HIV in serious diseases other than AIDS.
|
AIDS
|
2008
|
3.39
|
|
15
|
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
|
J Infect Dis
|
2008
|
3.35
|
|
16
|
Projected life expectancy of people with HIV according to timing of diagnosis.
|
AIDS
|
2012
|
3.09
|
|
17
|
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
|
J Infect Dis
|
2013
|
3.04
|
|
18
|
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
|
Antivir Ther
|
2008
|
2.93
|
|
19
|
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
|
AIDS
|
2010
|
2.85
|
|
20
|
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
|
Clin Trials
|
2012
|
2.71
|
|
21
|
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
2.70
|
|
22
|
Current epidemiology of Pneumocystis pneumonia.
|
Emerg Infect Dis
|
2004
|
2.70
|
|
23
|
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
|
Circulation
|
2008
|
2.64
|
|
24
|
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.
|
Crit Care Med
|
2015
|
2.62
|
|
25
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
|
26
|
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
|
AIDS
|
2008
|
2.27
|
|
27
|
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
|
J Infect Dis
|
2009
|
2.20
|
|
28
|
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
|
Circulation
|
2008
|
2.17
|
|
29
|
Chronic renal failure among HIV-1-infected patients.
|
AIDS
|
2007
|
2.07
|
|
30
|
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
|
Clin Infect Dis
|
2008
|
2.06
|
|
31
|
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.
|
AIDS
|
2014
|
2.02
|
|
32
|
Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis.
|
Clin Diagn Lab Immunol
|
2005
|
2.02
|
|
33
|
Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).
|
Circulation
|
2009
|
2.01
|
|
34
|
When should antiretroviral therapy for HIV be started?
|
BMJ
|
2007
|
1.95
|
|
35
|
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
|
AIDS
|
2009
|
1.90
|
|
36
|
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
|
J Infect Dis
|
2009
|
1.88
|
|
37
|
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.
|
AIDS
|
2009
|
1.81
|
|
38
|
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
|
Control Clin Trials
|
2002
|
1.73
|
|
39
|
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
|
Ann Intern Med
|
2002
|
1.70
|
|
40
|
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.
|
AIDS
|
2011
|
1.68
|
|
41
|
Cardiovascular implications from untreated human immunodeficiency virus infection.
|
Eur Heart J
|
2011
|
1.64
|
|
42
|
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.
|
Epidemiology
|
2011
|
1.59
|
|
43
|
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
|
Clin Infect Dis
|
2010
|
1.54
|
|
44
|
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.
|
Cancer
|
2010
|
1.53
|
|
45
|
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
|
AIDS
|
2005
|
1.52
|
|
46
|
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
|
AIDS
|
2006
|
1.52
|
|
47
|
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
|
AIDS
|
2007
|
1.51
|
|
48
|
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
|
Cancer
|
2004
|
1.39
|
|
49
|
The CD4 lymphocyte count and risk of clinical progression.
|
Curr Opin HIV AIDS
|
2006
|
1.38
|
|
50
|
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).
|
PLoS One
|
2013
|
1.36
|
|
51
|
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers.
|
AIDS
|
2013
|
1.34
|
|
52
|
Virological rebound after suppression on highly active antiretroviral therapy.
|
AIDS
|
2003
|
1.34
|
|
53
|
YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis.
|
Clin Diagn Lab Immunol
|
2002
|
1.29
|
|
54
|
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
|
J Infect Dis
|
2006
|
1.28
|
|
55
|
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe.
|
J Acquir Immune Defic Syndr
|
2006
|
1.27
|
|
56
|
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
|
AIDS
|
2008
|
1.25
|
|
57
|
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
|
J Infect Dis
|
2003
|
1.25
|
|
58
|
Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.
|
AIDS
|
2015
|
1.23
|
|
59
|
Aging with HIV in Africa: the challenges of living longer.
|
AIDS
|
2012
|
1.21
|
|
60
|
Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.
|
Am J Respir Crit Care Med
|
2008
|
1.21
|
|
61
|
The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
|
AIDS
|
2008
|
1.18
|
|
62
|
Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis.
|
J Infect Dis
|
2008
|
1.18
|
|
63
|
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
|
Antivir Ther
|
2005
|
1.18
|
|
64
|
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
|
AIDS
|
2005
|
1.16
|
|
65
|
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
|
AIDS
|
2012
|
1.16
|
|
66
|
Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome.
|
Scand J Infect Dis
|
2004
|
1.15
|
|
67
|
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
|
AIDS
|
2007
|
1.15
|
|
68
|
Predictors of hypertension and changes of blood pressure in HIV-infected patients.
|
Antivir Ther
|
2005
|
1.14
|
|
69
|
Monitoring of long-term toxicities of HIV treatments: an international perspective.
|
AIDS
|
2003
|
1.14
|
|
70
|
Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
|
J Infect Dis
|
2013
|
1.13
|
|
71
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
72
|
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
AIDS
|
2008
|
1.11
|
|
73
|
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
|
J Infect Dis
|
2004
|
1.09
|
|
74
|
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
|
AIDS
|
2007
|
1.07
|
|
75
|
Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study.
|
J Electrocardiol
|
2010
|
1.06
|
|
76
|
Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection.
|
Emerg Infect Dis
|
2007
|
1.05
|
|
77
|
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
|
78
|
The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients.
|
BMC Infect Dis
|
2008
|
1.04
|
|
79
|
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
|
AIDS
|
2014
|
1.03
|
|
80
|
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
|
Antivir Ther
|
2005
|
1.03
|
|
81
|
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
|
J Int AIDS Soc
|
2012
|
1.03
|
|
82
|
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
|
AIDS
|
2003
|
0.99
|
|
83
|
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
|
AIDS
|
2008
|
0.99
|
|
84
|
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
|
AIDS
|
2013
|
0.98
|
|
85
|
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.
|
Clin Infect Dis
|
2012
|
0.98
|
|
86
|
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
|
BMC Infect Dis
|
2013
|
0.98
|
|
87
|
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.
|
HIV Clin Trials
|
2011
|
0.98
|
|
88
|
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.
|
Int J Epidemiol
|
2007
|
0.96
|
|
89
|
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.
|
PLoS One
|
2012
|
0.95
|
|
90
|
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
|
AIDS
|
2003
|
0.95
|
|
91
|
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
|
Antivir Ther
|
2007
|
0.95
|
|
92
|
The metabolic syndrome in HIV.
|
Best Pract Res Clin Endocrinol Metab
|
2011
|
0.94
|
|
93
|
Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.
|
Diabetes Care
|
2008
|
0.94
|
|
94
|
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
|
J Infect Dis
|
2002
|
0.93
|
|
95
|
Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis.
|
BMC Infect Dis
|
2006
|
0.93
|
|
96
|
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
|
AIDS
|
2010
|
0.92
|
|
97
|
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
|
Antivir Ther
|
2006
|
0.92
|
|
98
|
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.
|
AIDS
|
2011
|
0.91
|
|
99
|
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.
|
AIDS
|
2011
|
0.91
|
|
100
|
Editorial commentary: universal antiretroviral therapy for HIV infection?
|
Clin Infect Dis
|
2013
|
0.91
|
|
101
|
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
|
Antivir Ther
|
2006
|
0.90
|
|
102
|
Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis.
|
Infect Immun
|
2004
|
0.89
|
|
103
|
Starting highly active antiretroviral therapy: why, when and response to HAART.
|
J Antimicrob Chemother
|
2004
|
0.89
|
|
104
|
In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging.
|
BMC Med Imaging
|
2008
|
0.89
|
|
105
|
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.
|
AIDS
|
2011
|
0.89
|
|
106
|
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
|
J Acquir Immune Defic Syndr
|
2008
|
0.89
|
|
107
|
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
|
Antivir Ther
|
2004
|
0.89
|
|
108
|
HIV survival benefit associated with earlier antiviral therapy.
|
Ann Intern Med
|
2004
|
0.88
|
|
109
|
Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.
|
AIDS
|
2014
|
0.87
|
|
110
|
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
|
Antivir Ther
|
2008
|
0.87
|
|
111
|
Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative.
|
Antivir Ther
|
2013
|
0.87
|
|
112
|
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.
|
Antivir Ther
|
2002
|
0.87
|
|
113
|
Deteriorating renal function and clinical outcomes in HIV-positive persons.
|
AIDS
|
2014
|
0.86
|
|
114
|
Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis.
|
J Neuroimmunol
|
2005
|
0.86
|
|
115
|
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
|
AIDS
|
2013
|
0.86
|
|
116
|
Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial.
|
BMJ Open
|
2012
|
0.86
|
|
117
|
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.
|
J Acquir Immune Defic Syndr
|
2012
|
0.86
|
|
118
|
Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.86
|
|
119
|
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.
|
AIDS
|
2015
|
0.85
|
|
120
|
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
|
Curr Opin HIV AIDS
|
2014
|
0.85
|
|
121
|
Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.
|
PLoS One
|
2013
|
0.85
|
|
122
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
|
AIDS
|
2012
|
0.85
|
|
123
|
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.
|
Cent Eur J Public Health
|
2008
|
0.84
|
|
124
|
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.
|
Scand J Infect Dis
|
2006
|
0.84
|
|
125
|
Biomarkers in HIV disease.
|
Curr Opin HIV AIDS
|
2010
|
0.84
|
|
126
|
Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe.
|
Eur Respir J
|
2013
|
0.83
|
|
127
|
Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis.
|
J Antimicrob Chemother
|
2006
|
0.83
|
|
128
|
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
|
Antivir Ther
|
2009
|
0.83
|
|
129
|
Platelet count kinetics following interruption of antiretroviral treatment.
|
AIDS
|
2013
|
0.83
|
|
130
|
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study.
|
Antivir Ther
|
2011
|
0.83
|
|
131
|
Haemoglobin and anaemia in the SMART study.
|
Antivir Ther
|
2011
|
0.82
|
|
132
|
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
|
Antivir Ther
|
2005
|
0.82
|
|
133
|
Guidelines for managing cardiovascular risk: an evolving area.
|
Curr Opin HIV AIDS
|
2008
|
0.82
|
|
134
|
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study.
|
BMC Infect Dis
|
2012
|
0.82
|
|
135
|
Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings.
|
Arch Intern Med
|
2009
|
0.82
|
|
136
|
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
|
PLoS One
|
2011
|
0.81
|
|
137
|
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
|
HIV Med
|
2007
|
0.81
|
|
138
|
Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study).
|
Am J Cardiol
|
2012
|
0.81
|
|
139
|
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
|
Antivir Ther
|
2012
|
0.81
|
|
140
|
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
|
J Infect Dis
|
2007
|
0.80
|
|
141
|
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
|
AIDS
|
2014
|
0.80
|
|
142
|
Antiretroviral therapy recommendations for the global community: aspiration versus reality.
|
AIDS
|
2014
|
0.80
|
|
143
|
Antibiotics in intensive care: too little or too much?
|
Crit Care Med
|
2011
|
0.79
|
|
144
|
Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.
|
Scand J Infect Dis
|
2005
|
0.79
|
|
145
|
Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
|
Scand J Infect Dis
|
2011
|
0.79
|
|
146
|
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study.
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
|
147
|
The natural history of HIV infection.
|
Curr Opin HIV AIDS
|
2013
|
0.78
|
|
148
|
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
|
Basic Clin Pharmacol Toxicol
|
2007
|
0.78
|
|
149
|
Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challenges.
|
Int J Epidemiol
|
2005
|
0.78
|
|
150
|
Incidence of abacavir hypersensitivity reactions in euroSIDA.
|
Antivir Ther
|
2008
|
0.78
|
|
151
|
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.
|
BMC Nephrol
|
2014
|
0.77
|
|
152
|
Update on HIV in Western Europe.
|
Curr HIV/AIDS Rep
|
2014
|
0.77
|
|
153
|
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
|
Scand J Infect Dis
|
2008
|
0.77
|
|
154
|
Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.
|
AIDS
|
2004
|
0.76
|
|
155
|
HIV resistance testing and detected drug resistance in Europe.
|
AIDS
|
2015
|
0.76
|
|
156
|
[Decline in AIDS and death rates in the EuroSIDA study. An observational study].
|
Ugeskr Laeger
|
2004
|
0.76
|
|
157
|
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
|
AIDS
|
2004
|
0.76
|
|
158
|
Novel biomarkers of infection in critically ill cancer patients: certainties and doubts*.
|
Crit Care Med
|
2014
|
0.75
|
|
159
|
Procalcitonin in liver transplant patients--yet another stone turned.
|
Crit Care
|
2008
|
0.75
|
|
160
|
Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy.
|
AIDS
|
2008
|
0.75
|
|
161
|
The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
|
AIDS
|
2016
|
0.75
|
|
162
|
Use of risk equations for predicting disease progression in HIV infection.
|
Clin Infect Dis
|
2009
|
0.75
|
|
163
|
Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs.
|
Pharmacoepidemiol Drug Saf
|
2003
|
0.75
|
|
164
|
"E" is for everything else, not least for expanding HIV testing in Europe.
|
Bull World Health Organ
|
2012
|
0.75
|
|
165
|
Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals.
|
Biomark Med
|
2014
|
0.75
|
|
166
|
Thrombocytopenia and cancer risk during HIV infection.
|
AIDS
|
2015
|
0.75
|
|
167
|
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?
|
AIDS
|
2016
|
0.75
|
|
168
|
Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio.
|
Clin Infect Dis
|
2009
|
0.75
|
|
169
|
System to classify cause of deaths in HIV-positive persons: time to harmonize.
|
AIDS
|
2012
|
0.75
|
|
170
|
Rescue of severely immunocompromised HIV-positive persons.
|
J Infect Dis
|
2010
|
0.75
|
|
171
|
The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial.
|
PLoS One
|
2013
|
0.75
|
|
172
|
Meta-analysis of procalcitonin for sepsis detection.
|
Lancet Infect Dis
|
2007
|
0.75
|
|
173
|
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
|
Antivir Ther
|
2011
|
0.75
|
|
174
|
The elusive search for an HIV vaccine--and what to do meanwhile.
|
Vaccine
|
2008
|
0.75
|
|
175
|
Are we successfully managing cardiovascular disease in people living with HIV?
|
Curr Opin HIV AIDS
|
2017
|
0.75
|
|
176
|
Associations between HIV-RNA-based indicators and virological and clinical outcomes.
|
AIDS
|
2016
|
0.75
|
|
177
|
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
|
178
|
Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients.
|
Shock
|
2017
|
0.75
|
|
179
|
Issues in the design of trials comparing management strategies for heavily pretreated patients.
|
Curr Opin HIV AIDS
|
2006
|
0.75
|
|
180
|
Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.75
|
|
181
|
The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial.
|
AIDS
|
2016
|
0.75
|
|
182
|
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines.
|
Curr Opin Infect Dis
|
2004
|
0.75
|
|
183
|
[Major breakthroughs in the medical treatment].
|
Ugeskr Laeger
|
2009
|
0.75
|
|
184
|
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
|
185
|
[Risk of virus transmission from well-treated patients with HIV?].
|
Ugeskr Laeger
|
2009
|
0.75
|
|
186
|
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
|
Antivir Ther
|
2003
|
0.75
|
|
187
|
Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia.
|
Transplantation
|
2017
|
0.75
|
|
188
|
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals.
|
AIDS
|
2016
|
0.75
|